This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
PENBRAYA offers the broadest protection against the 5 leading meningococcal serogroups (A, B, C, W, and Y) in a combination vaccine
Learn about ACIP-recommended dosing for PENBRAYA
PENBRAYA can streamline vaccination for your patients and practice
The CDC has issued a health advisory to alert healthcare providers to an increase in serogroup Y meningococcal disease.
The CDC has issued a health advisory to alert healthcare providers to an increase in serogroup Y meningococcal disease.
The Virginia Department of Health is responding to a statewide outbreak of meningococcal disease caused by the bacterium Neisseria meningitidis serogroup Y.
The Virginia Department of Health is responding to a statewide outbreak of meningococcal disease caused by the bacterium Neisseria meningitidis serogroup Y.
References: 1. Collins JP, Crowe JS, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices ― United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345-350. 2. PENBRAYA [prescribing information]. New York, NY: Pfizer Inc.; 2023. 3. Vaccines and preventable diseases: meningococcal vaccination. Centers for Disease Control and Prevention. Last reviewed November 20, 2023. Accessed January 22, 2024. https://www.cdc.gov/vaccines/vpd/mening/index.html 4. Enhanced meningococcal disease surveillance report, 2017. Centers for Disease Control and Prevention. Accessed June 27, 2024. https://stacks.cdc.gov/view/cdc/75419 5. Enhanced meningococcal disease surveillance report, 2018. Centers for Disease Control and Prevention. Accessed June 27, 2024. https://stacks.cdc.gov/view/cdc/111348 6. Enhanced meningococcal disease surveillance report, 2019. Centers for Disease Control and Prevention. Accessed October 27, 2023. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2019.pdf 7. Enhanced meningococcal disease surveillance report, 2020. Centers for Disease Control and Prevention. Accessed October 27, 2023. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2020.pdf 8. Enhanced meningococcal disease surveillance report, 2021. Centers for Disease Control and Prevention. Accessed October 27, 2023. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2021.pdf 9. Enhanced meningococcal disease surveillance report, 2022. Centers for Disease Control and Prevention. Accessed May 6, 2024. https://www.cdc.gov/meningococcal/downloads/ncird-ems-report-2022-508.pdf 10. Increase in invasive serogroup Y meningococcal disease in the United States. Centers for Disease Control and Prevention. Last reviewed March 28, 2024. Accessed May 3, 2024. https://emergency.cdc.gov/han/2024/han00505.asp 11. Surveillance and investigation: meningococcal disease outbreak response. Virginia Department of Health. Last reviewed Abril 2, 2024. Accessed May 3, 2024. https://www.vdh.virginia.gov/surveillance-and-investigation/meningococcal-disease-outbreak-response/
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.